{"entity":{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","aka":["HER2-positive brain metastases","Central nervous system metastases from HER2-positive breast cancer","Intracranial HER2-positive disease"],"tldr":"The brain is the weak point of HER2-positive breast cancer: antibodies control the rest of the body but cross poorly into the brain, so up to half of patients with advanced disease develop brain metastases. Tucatinib with trastuzumab and capecitabine was the first drug proven to help, and trastuzumab deruxtecan shrinks brain lesions in most patients.","summary":"Brain metastases became the signature problem of HER2-positive disease once trastuzumab began to control it elsewhere: antibodies are too large to cross an intact blood-brain barrier, so the brain was often the first and only site of progression. Lesions present with headache, seizures or focal deficits, or are found on staging MRI; guidelines do not recommend routine screening MRI, though the landmark trials required it. Local treatment follows the number and size of lesions: stereotactic radiosurgery for a limited number, which the Alliance N0574 trial showed preserves cognition better than adding whole-brain radiotherapy, surgery for a large symptomatic lesion, and whole-brain radiotherapy held back for many lesions or leptomeningeal spread.\n\nHER2CLIMB was the first randomised trial to enrol patients with active, untreated brain metastases and prove a drug helps them. It randomised 612 women who had received trastuzumab, pertuzumab and trastuzumab emtansine, almost half with brain metastases, to tucatinib or placebo with trastuzumab and capecitabine: progression-free survival rose from 5.6 to 7.8 months (hazard ratio 0.54), overall survival from 17.4 to 21.9 months (hazard ratio 0.66), and the risk of intracranial progression fell by about two thirds, leading to approval in April 2020. Earlier, lapatinib with capecitabine had shown intracranial responses in the single-arm LANDSCAPE study, and neratinib reduced the need for brain interventions in NALA; HER2CLIMB-02 later added tucatinib to trastuzumab emtansine with a modest gain concentrated in patients with brain disease, and HER2CLIMB-05 in 2025 showed tucatinib added to first-line antibody maintenance delays progression by more than eight months.\n\nTrastuzumab deruxtecan then showed that an antibody-drug conjugate can work inside the brain. Small phase 2 studies (TUXEDO-1, DEBBRAH) reported high intracranial response rates, and DESTINY-Breast12 treated 504 patients, 263 with brain metastases, with an intracranial objective response in 71.7 percent and 61.6 percent of the brain-metastasis cohort progression-free at twelve months, including patients whose lesions had not been irradiated. Because trastuzumab deruxtecan is also the second-line standard after DESTINY-Breast03, and first line with pertuzumab after DESTINY-Breast09, many patients now receive brain-active systemic therapy before the brain is ever involved. Whether systemic therapy should replace radiotherapy first in selected asymptomatic patients, how to treat leptomeningeal disease, and the risk of radionecrosis when radiosurgery and antibody-drug conjugates are combined are the open questions.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Brain_metastasis","links":[{"label":"HER2CLIMB (NEJM 2020)","url":"https://doi.org/10.1056/NEJMoa1914609"},{"label":"HER2CLIMB brain metastasis analysis (JCO 2020)","url":"https://doi.org/10.1200/JCO.20.00775"},{"label":"DESTINY-Breast12 (Nature Medicine 2024)","url":"https://www.nature.com/articles/s41591-024-03261-7"}],"tags":["subtype-page"],"related":["secondary-brain-tumours","her2-brain-metastases","brain-metastases","tucatinib-triplet-brain-mets","leptomeningeal-disease"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-brain-delivery"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"group":"breast","burden":"Up to half of women with metastatic HER2-positive breast cancer develop brain metastases during their illness, more than in any other breast subtype, partly because HER2 antibodies control disease elsewhere while the brain remains a sanctuary.","subtypes":["Asymptomatic HER2-positive brain metastases found on staging MRI (systemic therapy first under study)","Active or progressing HER2-positive brain metastases (HER2CLIMB population)","Stable, previously irradiated HER2-positive brain metastases","Leptomeningeal disease from HER2-positive breast cancer","Oligometastatic HER2-positive brain disease treated with stereotactic radiosurgery","HER2-positive brain metastases without extracranial progression"],"biomarkers":["HER2 status on the primary or an extracranial metastasis (brain biopsy rarely needed)","Contrast-enhanced brain MRI at baseline and every six to twelve weeks on treatment","Number, size and location of lesions (radiosurgery versus whole-brain radiotherapy)","Hormone receptor status","Cerebrospinal fluid cytology when leptomeningeal disease is suspected","Neurological performance status and corticosteroid requirement"],"standardOfCare":[{"setting":"Limited brain metastases at first presentation","approach":"Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.","refs":["radiosurgery-srs","stereotactic-radiosurgery","alliance-n0574","mri","brain-metastases"]},{"setting":"Active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine","approach":"Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.","refs":["tucatinib","trastuzumab","capecitabine","her2climb","her2-brain-metastases"]},{"setting":"Brain metastases, stable or active, second line","approach":"Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.","refs":["trastuzumab-deruxtecan","destiny-breast12","destiny-breast03"]},{"setting":"First-line maintenance to delay brain progression","approach":"Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).","refs":["tucatinib","trastuzumab","pertuzumab","her2climb-05"]},{"setting":"Later lines","approach":"Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.","refs":["neratinib","lapatinib","capecitabine","trastuzumab-emtansine","her2climb-02"]}],"stateOfArt":["HER2CLIMB proved a systemic drug can extend survival in patients with active brain metastases, and it changed trial eligibility rules across oncology.","Trastuzumab deruxtecan achieves intracranial responses in most patients, including untreated lesions.","Radiosurgery has replaced whole-brain radiotherapy for limited disease, preserving cognition.","Brain-metastasis cohorts are now written into first-line HER2 trials rather than excluded."],"history":[{"year":2003,"title":"Brain as the first site of progression on trastuzumab described","refs":["trastuzumab"]},{"year":2013,"title":"LANDSCAPE: lapatinib with capecitabine shrinks untreated brain metastases","refs":["lapatinib","capecitabine"]},{"year":2016,"title":"Alliance N0574: radiosurgery alone preserves cognition better than adding whole-brain radiotherapy","refs":["alliance-n0574"]},{"year":2020,"title":"HER2CLIMB: tucatinib approved, the first drug proven in active brain metastases","refs":["her2climb","tucatinib"]},{"year":2022,"title":"TUXEDO-1 and DEBBRAH: trastuzumab deruxtecan active in the brain","refs":["trastuzumab-deruxtecan"]},{"year":2023,"title":"HER2CLIMB-02: tucatinib with trastuzumab emtansine","refs":["her2climb-02"]},{"year":2024,"title":"DESTINY-Breast12: intracranial response in most patients","refs":["destiny-breast12"]},{"year":2025,"title":"HER2CLIMB-05: tucatinib in first-line maintenance","refs":["her2climb-05"]}],"pipeline":["trastuzumab-deruxtecan","tucatinib","her2climb-05","idea-cns-first-adc-strategy","zanidatamab","trastuzumab-rezetecan","pyrotinib","her2-pet"],"openProblems":["No randomised trial has compared systemic therapy first with radiosurgery first for asymptomatic lesions.","Leptomeningeal disease still has no proven treatment.","Radionecrosis after radiosurgery may be commoner with antibody-drug conjugates.","Screening MRI might find lesions earlier but no trial shows it helps."],"parent":"breast-her2-positive"},"route":"/cancers/her2-positive-breast-brain-metastases/","neighbours":{"cancer":[{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"term":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/"},{"id":"leptomeningeal-disease","kind":"term","name":"Leptomeningeal disease","route":"/terms/leptomeningeal-disease/"},{"id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/"}],"pairing":[{"id":"tucatinib-triplet-brain-mets","kind":"pairing","name":"Tucatinib + trastuzumab + capecitabine for brain metastases","route":"/pairings/tucatinib-triplet-brain-mets/"}],"bottleneck":[{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/"},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/"}],"trial":[{"id":"alliance-n0574","kind":"trial","name":"Alliance N0574 (NCCTG N0574)","route":"/trials/alliance-n0574/"},{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/"},{"id":"destiny-breast12","kind":"trial","name":"DESTINY-Breast12","route":"/trials/destiny-breast12/"},{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/"},{"id":"her2climb-02","kind":"trial","name":"HER2CLIMB-02","route":"/trials/her2climb-02/"},{"id":"her2climb-05","kind":"trial","name":"HER2CLIMB-05","route":"/trials/her2climb-05/"}],"idea":[{"id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/"}],"technology":[{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/"}]}}